SWK Holdings Announces Monetization of Royalty Portfolio
SWK Holdings (NASDAQ:SWKH) has announced the monetization of its royalty portfolio through two significant transactions. ANI Pharmaceuticals exercised its Iluvien royalty buyout option on March 17, 2025, resulting in a $17.3 million payment to SWK. Additionally, SWK has entered into an agreement with Soleus Capital to sell its remaining performing royalty portfolio for approximately $34.0 million in cash.
The combined monetization value of approximately $51.3 million represents a gain of $1.0 million over the portfolio's book value of $50.3 million as of December 31, 2024. The Soleus transaction is expected to close in two weeks, subject to customary conditions. SWK plans to declare a dividend to shareholders following the Soleus transaction closing, with the amount and record date to be announced at that time.
SWK Holdings (NASDAQ:SWKH) ha annunciato la monetizzazione del suo portafoglio di royalty attraverso due transazioni significative. ANI Pharmaceuticals ha esercitato l'opzione di acquisto delle royalty di Iluvien il 17 marzo 2025, risultando in un pagamento di 17,3 milioni di dollari a SWK. Inoltre, SWK ha stipulato un accordo con Soleus Capital per vendere il suo restante portafoglio di royalty performanti per circa 34,0 milioni di dollari in contanti.
Il valore combinato della monetizzazione, pari a circa 51,3 milioni di dollari, rappresenta un guadagno di 1,0 milione di dollari rispetto al valore contabile del portafoglio di 50,3 milioni di dollari al 31 dicembre 2024. Si prevede che la transazione con Soleus si concluda entro due settimane, soggetta a condizioni consuete. SWK prevede di dichiarare un dividendo agli azionisti dopo la chiusura della transazione con Soleus, con l'importo e la data di registrazione che saranno annunciati in quel momento.
SWK Holdings (NASDAQ:SWKH) ha anunciado la monetización de su cartera de regalías a través de dos transacciones significativas. ANI Pharmaceuticals ejerció su opción de compra de regalías de Iluvien el 17 de marzo de 2025, resultando en un pago de 17,3 millones de dólares a SWK. Además, SWK ha llegado a un acuerdo con Soleus Capital para vender su cartera restante de regalías rentables por aproximadamente 34,0 millones de dólares en efectivo.
El valor combinado de la monetización de aproximadamente 51,3 millones de dólares representa una ganancia de 1,0 millón de dólares sobre el valor contable de la cartera de 50,3 millones de dólares a 31 de diciembre de 2024. Se espera que la transacción con Soleus se cierre en dos semanas, sujeta a condiciones habituales. SWK planea declarar un dividendo a los accionistas tras el cierre de la transacción con Soleus, con el monto y la fecha de registro que se anunciarán en ese momento.
SWK Holdings (NASDAQ:SWKH)는 두 가지 주요 거래를 통해 로열티 포트폴리오의 수익화를 발표했습니다. ANI Pharmaceuticals는 2025년 3월 17일에 Iluvien 로열티 매수 옵션을 행사하여 SWK에 1,730만 달러를 지급했습니다. 또한, SWK는 Soleus Capital와 협력하여 남아 있는 성과 로열티 포트폴리오를 약 3,400만 달러에 현금으로 판매하는 계약을 체결했습니다.
약 5,130만 달러의 통합 수익화 가치는 2024년 12월 31일 기준 포트폴리오의 장부 가치인 5,030만 달러에 비해 100만 달러의 이익을 나타냅니다. Soleus와의 거래는 일반적인 조건에 따라 2주 이내에 마무리될 것으로 예상됩니다. SWK는 Soleus 거래 마감 후 주주들에게 배당금을 선언할 계획이며, 그 금액과 기준일은 그때 발표될 예정입니다.
SWK Holdings (NASDAQ:SWKH) a annoncé la monétisation de son portefeuille de redevances à travers deux transactions significatives. ANI Pharmaceuticals a exercé son option de rachat de redevances Iluvien le 17 mars 2025, entraînant un paiement de 17,3 millions de dollars à SWK. De plus, SWK a conclu un accord avec Soleus Capital pour vendre son portefeuille de redevances performantes restantes pour environ 34,0 millions de dollars en espèces.
La valeur combinée de la monétisation d'environ 51,3 millions de dollars représente un gain de 1,0 million de dollars par rapport à la valeur comptable du portefeuille de 50,3 millions de dollars au 31 décembre 2024. La transaction avec Soleus devrait être finalisée dans deux semaines, sous réserve des conditions habituelles. SWK prévoit de déclarer un dividende aux actionnaires après la clôture de la transaction avec Soleus, le montant et la date d'enregistrement étant annoncés à ce moment-là.
SWK Holdings (NASDAQ:SWKH) hat die Monetarisierung seines Lizenzportfolios durch zwei bedeutende Transaktionen angekündigt. ANI Pharmaceuticals hat am 17. März 2025 die Kaufoption für die Iluvien-Lizenz ausgeübt, was zu einer Zahlung von 17,3 Millionen Dollar an SWK führt. Darüber hinaus hat SWK eine Vereinbarung mit Soleus Capital getroffen, um sein verbleibendes leistungsfähiges Lizenzportfolio für etwa 34,0 Millionen Dollar in bar zu verkaufen.
Der kombinierte Monetarisierungswert von etwa 51,3 Millionen Dollar stellt einen Gewinn von 1,0 Million Dollar gegenüber dem Buchwert des Portfolios von 50,3 Millionen Dollar zum 31. Dezember 2024 dar. Die Soleus-Transaktion wird voraussichtlich in zwei Wochen abgeschlossen, vorbehaltlich üblicher Bedingungen. SWK plant, nach Abschluss der Soleus-Transaktion eine Dividende an die Aktionäre zu erklären, deren Höhe und Stichtag zu diesem Zeitpunkt bekannt gegeben werden.
- Monetization of royalty portfolio at $51.3M, representing a $1.0M premium over book value
- Upcoming dividend distribution to shareholders
- Successful execution of two separate monetization transactions
- Divestment of substantially all performing royalty assets may impact future recurring revenue streams
DALLAS, TX / ACCESS Newswire / March 19, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the monetization of its royalty portfolio through two transactions.
On March 17, 2025, ANI Pharmaceuticals, Inc. exercised its buyout option related to the Iluvien royalty, which resulted in a payment of approximately
"The monetization of our royalty portfolio at a premium to book value demonstrates our commitment to realizing the underlying value of our assets," said Jody Staggs, Chief Executive Officer of SWK Holdings Corporation. "In conjunction with the closing of the Soleus transaction, SWK anticipates declaring a dividend to its shareholders. The amount and the record date of the dividend are expected to be declared in connection with the transaction closing."
About SWK Holdings Corporation
SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the Company's expectations regarding the timing and results of the transaction closings and the Company's expectations related to the anticipated declaration of a cash dividend to Company stockholders. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
For more information, please contact:
Investor Relations and Media
Susan Xu
investorrelations@swkhold.com
778-323-0959
SOURCE: SWK Holdings Corp.
View the original press release on ACCESS Newswire
FAQ
What is the total value of SWK Holdings' royalty portfolio monetization in March 2025?
How much premium did SWKH receive over book value for its royalty portfolio sale?
When will SWKH shareholders receive the dividend from the royalty portfolio sale?
What was the value of ANI Pharmaceuticals' Iluvien royalty buyout from SWKH?
